Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Radiation Retinopathy (ARRT)
NCT03085784Phase 2Unknown
- Start
- Jul 2017
- Primary completion
- Oct 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in radiation retinopathy (RR) (2 arms). Primary endpoint: Safety of intravitreal Aflibercept for the treatment of radiation retinopathy at 52 weeks. Status: unknown.
02
Drugs
aflibercept
03
Conditions
radiation retinopathy (RR)
Beyond the preview
Go deeper on NCT03085784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085784.